MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
Rhea-AI Summary
MiniMed (NASDAQ: MMED) announced an expanded agreement with Abbott to commercialize integrated dual glucose-ketone sensors designed to work exclusively with MiniMed smart dosing systems.
The same-size-as-Instinct sensors aim to enable early, real-time ketone detection to help prevent diabetic ketoacidosis (DKA). Abbott’s dual systems have CE Mark, are under FDA review, and are not yet cleared or available in the United States.
AI-generated analysis. Not financial advice.
Positive
- Expanded collaboration with Abbott on integrated dual glucose-ketone sensors
- Exclusive integration with MiniMed automated insulin delivery and Smart MDI systems
- Real-time ketone data designed to support earlier DKA risk alerts and intervention
- Sensors match the size of Instinct, described as the world’s smallest, thinnest sensor
Negative
- Abbott dual glucose-ketone systems are not yet cleared or available in the United States
- Regulatory and commercialization milestones remain pending, with sensors not yet available to users
Market Reaction – MMED
Following this news, MMED has gained 5.82%, reflecting a notable positive market reaction. The stock is currently trading at $13.02. This price movement has added approximately $190M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Surgical & Medical Instruments space appeared in the momentum scanner, suggesting MMED’s 2.5% move is driven by company-specific news around the Abbott sensor collaboration.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | Product showcase | Positive | -3.4% | Plans to showcase MiniMed Flex and MiniMed Go at ADA scientific meeting. |
| May 26 | Conference participation | Neutral | -5.8% | Announcement of participation in Goldman Sachs global healthcare conference. |
| May 21 | Clinical outcomes data | Positive | +0.8% | Trial showed consistent strong glycemic outcomes across sensors with 780G. |
| Apr 13 | Earnings date set | Neutral | +5.7% | Scheduled Q4 and full-year 2026 earnings release and webcast details. |
| Mar 18 | FDA clearance | Positive | -0.2% | FDA cleared MiniMed Flex smartphone-controlled insulin pump ahead of schedule. |
Recent history shows MMED often selling off or staying flat on positive operational news, with 3 of the last 5 news events seeing price moves that diverged from the underlying sentiment.
Over the last six months, MiniMed has highlighted major product and strategic milestones, including FDA clearance of MiniMed Flex™, a study confirming strong glycemic outcomes across sensors on the 780G system, and upcoming Q4/FY26 results on June 3, 2026. Despite these positives, shares frequently moved lower on good news. Today’s expanded Abbott collaboration on dual glucose‑ketone sensors fits the theme of deepening its technology ecosystem for automated insulin delivery.
Market Pulse Summary
This announcement expands MiniMed’s collaboration with Abbott to integrate dual glucose‑ketone sensors into its smart dosing systems, targeting earlier detection of DKA risk. The news builds on prior Instinct sensor work and supports MiniMed’s broader automated insulin strategy. Investors may watch for regulatory milestones, commercialization timelines, real‑world performance data, and how these sensors are bundled across MiniMed Flex, 780G, and Go platforms in the coming months.
Key Terms
diabetic ketoacidosis medical
ketone monitoring medical
ce mark regulatory
AI-generated analysis. Not financial advice.
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management
These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA), a life-threatening complication.1 The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott, and will offer MiniMed users expanded choice across its automated insulin delivery and Smart MDI systems. The sensors will be the same size as the Instinct sensor, the world's smallest and thinnest sensor.2,3
"By integrating dual glucose-ketone monitoring sensors with our MiniMed smart dosing systems, we're adding an additional layer of intelligence and protection," said Que Dallara, chief executive officer, MiniMed. "Our system is designed to keep people in tight glucose control and minimize DKA risk through smarter, more consistent automation — intervening before it ever becomes an emergency. This partnership with Abbott takes that commitment even further. At MiniMed, our mission is to make every day a better day for people with diabetes, and that means relentlessly pursuing innovations that not only improve outcomes but also deliver genuine peace of mind."
DKA is responsible for hundreds of thousands of hospitalizations annually in
The companies expect to provide further updates on regulatory and commercialization milestones in the coming months.
Abbott's dual glucose-ketone systems are not yet cleared or available for sale in
Frequently Asked Questions:
How will the dual glucose-ketone sensors work with MiniMed's insulin delivery system?
The dual sensors will be fully integrated with MiniMed's smart dosing systems and is designed to provide continuous glucose and ketone data directly to its intelligent dosing algorithm. While the glucose data informs real-time automated insulin delivery decisions, the ketone data adds an additional layer of safety by enabling earlier alerts when ketone levels begin to rise above a safe level — potentially enabling intervention before DKA develops.
What is DKA and why is continuous ketone monitoring important?
Diabetic ketoacidosis (DKA) is a serious, life-threatening complication of diabetes that occurs when the body produces dangerously high levels of ketones (acid molecules) due to insufficient insulin. DKA is the leading cause of death in children and adults under age 58 with type 1 diabetes and accounts for hundreds of thousands of hospitalizations each year.1 Continuous ketone monitoring is important because it can detect rising ketones in real time — before symptoms appear — enabling earlier intervention and potentially preventing emergency hospitalization.
Who would the dual sensors potentially be indicated for?
We anticipate the dual glucose-ketone sensors would be available for the same users indicated to use MiniMed systems today. This includes those with type 1 or insulin-requiring type 2 diabetes using MiniMed AID systems, and those with type 1 or type 2 diabetes using MiniMed Go.†
Is the sensor available?
Not yet. Abbott recently received CE Mark for its dual glucose-ketone system, which are also under FDA review. Additional details on the partnership will be shared in the coming months.
†Proper pairing, connectivity, and settings required or incorrect dosing and serious injury can occur. Ages 2-6 require caregiver supervision. See user guide for full details.
1. Umpierrez, et al. Diabetes Care (2024): https://doi.org/10.2337/dci24-0032.
2. Among patient-applied sensors.
3. Data on file. Abbott Diabetes Care, Inc.
4. Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's filings with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-expand-sensor-portfolio-with-integrated-dual-glucose-ketone-sensors-made-by-abbott-302789583.html
SOURCE MiniMed